Journey Medical Corporation (NASDAQ:DERM) announced topline data from the Phase 1 clinical trial assessing the impact of DFD-29 on the microbial flora of healthy adults. The clinical trial also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results